US 12,002,558 B2
Systems and methods for dispensing a statin medication over the counter
James Blasetto, Chadds Ford, PA (US); Judy Firor, Landenberg, PA (US); David Guiga, West Chester, PA (US); William Mongan, Malvern, PA (US); Robert Prybolsky, West Chester, PA (US); and Richard L. Skelly, Flourtown, PA (US)
Assigned to ASTRAZENECA UK LIMITED, Cambridge (GB)
Filed by ASTRAZENECA UK LIMITED, Cambridge (GB)
Filed on Aug. 29, 2022, as Appl. No. 17/898,115.
Application 17/898,115 is a continuation of application No. 17/132,731, filed on Dec. 23, 2020, granted, now 11,430,555.
Application 17/132,731 is a continuation of application No. 16/872,251, filed on May 11, 2020, granted, now 10,910,091, issued on Feb. 2, 2021.
Application 16/872,251 is a continuation in part of application No. 16/791,745, filed on Feb. 14, 2020, granted, now 11,031,104, issued on Jun. 8, 2021.
Application 16/791,745 is a continuation of application No. 15/385,747, filed on Dec. 20, 2016, granted, now 10,600,502, issued on Mar. 24, 2020.
Prior Publication US 2023/0005584 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 20/10 (2018.01); A61K 31/505 (2006.01); G16H 50/30 (2018.01)
CPC G16H 20/10 (2018.01) [A61K 31/505 (2013.01); G16H 50/30 (2018.01)] 27 Claims
OG exemplary drawing
 
1. A method of managing cholesterol in a subject, the method comprising:
at a computer system comprising one or more processors and a memory, the memory comprising non-transitory instructions which, when executed by the one or more processor, perform an algorithm comprising:
a) receiving a request for a statin pharmaceutical composition;
b) obtaining information, about the subject, comprising:
an age of the subject,
a gender of the subject,
when the subject is female, whether the subject is pregnant or breastfeeding,
a race with which the subject identifies,
whether the subject is taking one or more medications that interact with the statin pharmaceutical composition,
whether the subject has had an atherosclerotic cardiovascular event;
data required by a pooled cohort equation that calculates a risk of the subject developing an atherosclerotic disease;
whether the subject has liver disease,
an alcohol consumption status of the subject, and
whether the subject has had an adverse reaction to a cholesterol lowering medication;
c) comparing all or a portion of the information about the subject against a plurality of filters, wherein the plurality of filters comprises a filter of a first type and a filter of a second type and, when a respective filter in the plurality of filters is fired by the comparing, the subject is deemed unqualified for delivery of the statin pharmaceutical composition when the respective filter is of the first type or the subject is provided with a warning corresponding to the respective filter when the respective filter is of the second type, and wherein the plurality of filters comprises:
an age filter,
a pregnancy filter,
a drug interaction filter,
an atherosclerotic cardiovascular event filter;
a pooled cohort equation filter,
a liver disease filter,
an alcohol consumption filter, and
an adverse reaction filter; and
d) when each filter in the plurality of filters that is configured to deem the subject unqualified for delivery of the statin pharmaceutical composition when fired has not been fired:
obtaining a corresponding acknowledgement from the subject for each respective warning associated with each filter in the plurality of filters that was fired in the comparing c) that is not configured to deem the subject unqualified for delivery of the statin pharmaceutical composition when fired, wherein the corresponding acknowledgment is confirmation that the subject has discussed the respective warning with a medical practitioner, and
authorizing a provision of the statin pharmaceutical composition; the method further comprising:
administering the statin pharmaceutical composition to the subject, upon authorization of the provision, to manage cholesterol in the subject.